FC050: Nefecon® Selectively Modifies the Composition of Circulating Immune Complexes in IGA Nephropathy

医学 肾病 安慰剂 蛋白尿 内科学 免疫学 胃肠病学 免疫系统 肾小球肾炎 内分泌学 病理 肾 糖尿病 替代医学
作者
Karen Molyneux,Katrin Scionti,Witold Wolski,Sibylle Pfammatter,Laura Kunz,Atef Mahmoud Mannaa,Jonathan Barratt
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
卷期号:37 (Supplement_3) 被引量:4
标识
DOI:10.1093/ndt/gfac107.002
摘要

Abstract BACKGROUND AND AIMS IgA nephropathy (IgAN) is characterized by the mesangial deposition of IgA-containing immune complexes (IgA-IC). There is, however, no clear association between extent of mesangial IgA-IC deposition and disease severity in IgAN, suggesting that the composition of the IgA-IC, rather than the actual amount, may be critical in determining pathogenic consequences. The NEFIGAN trial (NCT01738035) assessed the safety and efficacy of a novel targeted-release formulation of budesonide (Nefecon®), designed to deliver the drug to the gut-associated lymphoid tissue (GALT)-rich distal ileum in patients with IgAN. The trial comprised a 6-month run-in, a 9-month treatment and a 3-month follow-up phase. A total of 48 patients received Nefecon® 16 mg/day, 51 patients received Nefecon® 8 mg/day and 50 patients received placebo. The key result of the study was that Nefecon® 16 mg/day, added to optimized renin–angiotensin system blockade, reduced proteinuria and stabilized estimated glomerular filtration rate in patients with IgAN. These findings have now been replicated in the NefIgArd study, which released data in 2021. Here, we report the composition of IgA-IC in the serum of patients treated with Nefecon® 16 mg/day or placebo in the NEFIGAN trial, assessed using liquid chromatography with tandem mass spectrometry (LC-MS/MS). This study was supported by a grant from Calliditas Therapeutics AB. METHOD Using Jacalin Agarose and elution with 0.1 M d-galactose, IgA-ICs were affinity-purified from serum of patients who received placebo (n=18) or Nefecon® 16 mg/day (n=18) at the start of treatment (SOT) and end of treatment (EOT). All protein samples were reduced and alkylated prior to digestion with trypsin, dried using a Savant SpeedVac (Thermo Fisher Scientific, UK) and dissolved in 40 µL of 0.1% formic acid. Each sample, spiked with iRT standard peptides (Biognosys, Switzerland), was loaded onto an Evotip (Evosep Biosystems, Denmark) column. Mass spectrometry analyses were performed on the Evosep One (Evosep) platform, coupled to the TIMS TOF Pro (Bruker, US). For protein identification and quantification, raw data were processed with FragPipe (V16), based on at least two peptides per protein. The protein intensities thus generated were Log_2-transformed and internally normalized using IGHA1 protein as standard. For each patient, the normalized protein amount at SOT was subtracted from the amount at EOT. A probabilistic dropout model was applied to the data to estimate fold changes between treatment and placebo groups at EOT. The proteins were ranked using t-statistic, and a gene set enrichment analysis was performed to determine the gene sets significantly affected by Nefecon® 16 mg/day versus placebo. RESULTS Gene ontology analysis revealed that treatment with Nefecon® 16 mg/day led to a significant protein enrichment in IgA-IC associated with pathways driving biological processes involved in the negative regulation of gene expression and transcription, gene silencing and epigenetics. In parallel, treatment with Nefecon® was also associated with an enrichment of proteins associated with extracellular vesicle and exosome formation. CONCLUSION For the first time, we show that it is possible to pharmacologically modify the composition of circulating IgA-IC in IgAN. Treatment with Nefecon® 16 mg/day for 9 months selectively altered the protein composition of IgA-IC in a way that is likely to have significant consequences on the downstream mesangial response to IgA-IC accumulation; this may, in part, explain the antiproteinuric effect of this approach and the longer-term kidney function protection that has been reported in both the NEFIGAN and NefIgArd clinical trials. Studies are ongoing to precisely delineate the impact of these compositional changes on the pathogenicity of IgA-IC in IgAN.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
搜集达人的应助被科研通管家采纳,获得10
刚刚
资明轩完成签到,获得积分10
刚刚
汉堡包的应助被科研通管家采纳,获得10
刚刚
6666的应助被科研通管家采纳,获得20
刚刚
今后的应助被科研通管家采纳,获得10
1秒前
慕青的应助被科研通管家采纳,获得10
1秒前
思源的应助被科研通管家采纳,获得10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
1秒前
烟花的应助被科研通管家采纳,获得10
1秒前
无花果的应助被科研通管家采纳,获得10
1秒前
Xide完成签到,获得积分10
1秒前
moon完成签到,获得积分10
1秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
田様的应助被科研通管家采纳,获得10
2秒前
小蘑菇的应助被科研通管家采纳,获得10
2秒前
achilles发布了新的文献求助10
2秒前
酷波er的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
大模型的应助被科研通管家采纳,获得10
2秒前
2秒前
Owen的应助被你很棒采纳,获得30
2秒前
3秒前
3秒前
4秒前
风吹麦浪的应助被名古邬采纳,获得20
4秒前
初景发布了新的文献求助10
5秒前
今后的应助被斯多姆采纳,获得10
5秒前
5秒前
Eternity完成签到,获得积分10
5秒前
天天快乐的应助被Jase采纳,获得10
6秒前
津津完成签到,获得积分10
6秒前
yosh发布了新的文献求助10
6秒前
十一完成签到 ,获得积分10
6秒前
jie发布了新的文献求助10
7秒前
莓莓发布了新的文献求助10
7秒前
冰棍发布了新的文献求助10
7秒前
苁蓉远志完成签到 ,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527